Novo Nordisk A/S-BNONOF
13F holders, Q4 2024 (December 31)3holders +1
1new positions
0sold out
$85.90avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Novo Nordisk A/S-B (NONOF) in their 13F filings, up 1 from Q3 2024. 1 opened new positions and 0 sold out. The largest holders were LBMC Investment Advisors, LLC ($877K), Atlas Capital Advisors Inc. ($448K) and GAMMA Investing LLC ($67K).
- Company
- Novo Nordisk A/S-B
- CUSIP
- K72807140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $877K |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 10,730 shares bought, net +10,730 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| LBMC Investment Advisors, LLC | 0.07% | New | 10,210 | $877K |
| Atlas Capital Advisors Inc. | 0.06% | No change | 5,218 | $448K |
| GAMMA Investing LLC | 0.01% | Add +201.6% | 778 | $67K |
"% of holder's portfolio" is NONOF's weight in each manager's 13F, not the share of Novo Nordisk A/S-B the manager owns.